2-((2S,5R,8S,11S)-8-(4-Aminobutyl)-5-Benzyl-11-(3-Guanidinopropyl)-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-Yl)Acetic Acid Trifluoroacetate 2-((2S,5R,8S,11S)-8-(4-氨基丁基)-5-苄基-11-(3-胍基丙基)-3,6,9,12,15-五氧代-1,4,7,10,13-五氮杂环十五烷-2-基)乙酸三氟乙酸盐
CAS 500577-51-5 MFCD00577515
化学结构图
SMILES:
别名和识别编码
| Chemical Name Translation | 2-((2S,5R,8S,11S)-8-(4-氨基丁基)-5-苄基-11-(3-胍基丙基)-3,6,9,12,15-五氧代-1,4,7,10,13-五氮杂环十五烷-2-基)乙酸三氟乙酸盐 |
|---|---|
| Chemical Name | 2-((2S,5R,8S,11S)-8-(4-Aminobutyl)-5-Benzyl-11-(3-Guanidinopropyl)-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-Yl)Acetic Acid Trifluoroacetate |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
相关文献及参考
- [2]. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.
- [1]. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.
- [1]. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.
- [2]. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.
